* Nevro Corp reported a quarterly adjusted loss of 41 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -65 cents. The mean expectation of fifteen analysts for the quarter was for a loss of 81 cents per share. Wall Street expected results to range from -98 cents to -62 cents per share.

* Revenue fell 6.7% to $96.91 million from a year ago; analysts expected $93.07 million.

* Nevro Corp's reported EPS for the quarter was a loss of 41 cents​.

* The company reported a quarterly loss of $15.34 million.

* Nevro Corp shares had fallen by 9.1% this quarter and lost 76.4% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 2.6% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 12 "hold" and 4 "sell" or "strong sell."

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "hold"

Wall Street's median 12-month price target for Nevro Corp is 7.00 This summary was machine generated from LSEG data November 12 at 03:42 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.81 -0.41 Beat

Jun. 30 2024 -0.68 -0.53 Beat

Jan. 1 0001 -1.05 -0.58 Beat

Dec. 31 2023 -0.49 -0.25 Beat